Advanced Search
Disease Phase
Title Drug
Clinical Trials Listing
  • < Previous
  • 1
  • Next >
  • Penn Treatment Trials (12)
  • Penn Non-Treatment Trials (6)
  • Phase 1: Solid Tumor Trials (3)
  • Proton Therapy Trials (2)
Active treatment trials at Penn's Abramson Cancer Center
Protocol ID Title Phase Modality Drug
CALGB-90601 A Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin, and Placebo in Patients With Advanced Transitional Cell Carcinoma III Angiogenesis Inhibitor, Chemotherapy cisplatin; gemcitabine; bevacizumab
SWOG-S0931 EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study III Signal Transduction Inhibitor everolimus
113387 A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Pazopanib as Adjuvant Therapy for Subjects With Localized or Locally Advanced RCC Following Nephrectomy III Other, Signal Transduction Inhibitor pazopanib
UPCC 09712 NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition (TKI) at Recurrence After Adjuvant Therapy in Renal Cell Carcinoma (RCC) II Signal Transduction Inhibitor axitinib
ECOG-E1808 A Randomized Phase II Trial of Sunitinib/Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma With Sarcomatoid Features II Angiogenesis Inhibitor, Chemotherapy gemcitabine; sunitinib
UPCC 19811 Feasibility and Phase 1/II Trial of Adjuvant Radiation Therapy for the Treatment of Urothelial Bladder Cancer Using Proton Therapy or IMRT I / II Radiotherapy, Proton Therapy Not Applicable
AEZS-108-046 A Phase I/II Trial of AEZS-108 in Locally Advanced Unresectable or Metastatic Luteinizing Hormone-releasing Hormone(LHRH) Positive Urothelial Carcinoma Patients Who Failed Platinum Based Chemotherapy I / II Biological Therapy zoptarelin doxorubicin
UPCC 07811 Autophagy Inhibition to Augment mTOR Inhibition: A Phase I/II Trial of RAD001 and Hydroxychloroquine in Patients With Previously Treated Renal Cell Carcinoma I / II Signal Transduction Inhibitor everolimus; hydroxychloroquine
UPCC 02812 Phase 1b Study Of CRLX 101 (Cerulean) In Combination With Bevacizumab In The Treatment Of Patients With Advanced Renal Cell Carcinoma I Chemotherapy, Signal Transduction Inhibitor bevacizumab; CRLX101
CA186-011 A Phase 1 Study of the Safety, Tolerability, Pharmacokinetics and Immunoregulatory Activity of BMS-663513 (Anti-CD137) in Subjects With Advanced and/or Metastatic Solid Tumors I Immunotherapy BMS-663513
UPCC 34809 Assessment of Tumor Perfusion Changes in Response to Pazopanib in Renal Cell Carcinoma 0 Signal Transduction Inhibitor pazopanib
UPCC-03809 An Imaging and Histopathologic Study to Predict Response to Sunitinib Therapy in Patients With Metastatic Renal Cell Carcinoma Not Specified Angiogenesis Inhibitor sunitinib
Displaying: 1 - 12 of 12 Results
  • < Previous
  • 1
  • Next >